当前位置: 首页 > 期刊 > 《世界中医药》 > 20177
编号:13616800
扶正消瘤汤辅助化疗对乳腺癌患者术后肿瘤标志物水平及免疫功能的影响(1)
http://www.100md.com 2017年4月1日 《世界中医药》 20177
     摘要 目的:探討扶正消瘤汤辅助化疗对乳腺癌患者术后肿瘤标志物水平及免疫功能的影响。方法:选取乳腺癌患者74例,根据电脑产生的随机数字分为观察组和对照组,各37例,2组患者均给予常规化疗方案,观察组在此基础上增加扶正消瘤汤治疗。比较2组患者治疗后血清肿瘤标志物水平,治疗前后免疫功能及乳腺癌生命质量测评量表(FACT-B)评分。结果:治疗后观察组血清CEA、CA125、CA153、TSGF、VEGF-A、IGF-1及TK1水平均明显低于对照组( P <0.05或 P <0.01);治疗后对照组CD3+、CD4+比例明显低于治疗前,观察组CD3+、CD4+比例及CD4+/CD8+均明显高于治疗前,CD8+比例明显低于治疗前,差异有统计学意义( P <0.05或 P <0.01),且2组间差异有统计学意义( P <0.01),NK细胞比例治疗前后及2组间比较均无明显变化,差异无统计学意义( P >0.05);治疗后观察组FACT-B评分明显升高,且明显高于对照组,差异有统计学意义( P <0.01)。结论:乳腺癌患者化疗期间给予扶正消瘤汤可以明显提高机体免疫功能,降低血清肿瘤标志物水平,提高患者生命质量,一定程度上减少患者术后复发或转移。
, http://www.100md.com
    关键词 乳腺癌;化疗;扶正消瘤汤;肿瘤标志物;免疫功能;生命质量

    Adjuvant Effect of Fuzheng Xiaoliu Decoction for Chemotherapy on Tumor Markers and immunity of Postoperative Breast Cancer Patients

    Zhou Shifan

    (Oncology Department, The Second Affiliated Hospital of Henan University of TCM, Zhengzhou 450002, China)

    Abstract Objective: To explore adjuvant effect of Fuzheng Xiaoliu Decoction for chemotherapy on tumor markers and immunity of postoperative breast cancer patients. Methods: A total of 74 breast cancer patients were selected and divided into treatment group and control group according to the random numbers generated by computer, with 37 cases in each group. The two groups were treated with conventional chemotherapy, while treatment group additionally treated with Fuzheng Xiaoliu Decoction. Levels of tumor markers, immunity and the scores of Functional Assessment of Cancer Therapy-Breast Quality of Life Instrument (FACT-B) in the two groups before and after the treatment were compared. Results: The levels of serum CEA, CA125, CA153, TSGF, VEGF-A, IGF-1 and TK1 in the treatment group after the treatment decreased significantly compared with those before the treatment ( P <0.05 or P <0.01). The proportion of CD3+, CD4+ in the control group decreased significantly after the treatment. The proportion of CD3+, CD4+ and CD4+/CD8+ increased significantly and the proportion of CD8+ decreased significantly in the treatment group ( P <0.05 or P <0.01), with significant difference between the two groups ( P <0.05 or P <0.01). The proportion of NK cell had no significant difference ( P >0.05). The FACT-B scores in the treatment group after the treatment increased significantly and were higher than those in the control group ( P <0.01). Conclusion: Fuzheng Xiaoliu Decoction adjuvant to chemotherapy can improve immune function of patients with breast cancer, reduce levels of serum tumor markers, enhance life quality of breast cancer patients and reduce postoperative recurrence or metastasis to some extent., 百拇医药(周世繁)
1 2 3下一页